αβ T-cell receptor engineered γδ T cells mediate effective antileukemic reactivity

Cancer Research

Volumn 66, Issue 6, 2006, Pages 3331-3337

  Van Der Veken, Lars T ^a   Hagedoorn, Renate S ^a   Van Loenen, Marleen M ^a   Willemze, Roel ^a   Falkenburg, J H Frederik ^a   Heemskerk, Mirjam H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 4; MINOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR; HLA A2 ANTIGEN; HLA B7 ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; EFFECTOR CELL; GENE TRANSFER; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS VECTOR; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNOLOGY; ADOPTIVE IMMUNOTHERAPY; BIOSYNTHESIS; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; METHODOLOGY; RETROVIRUS;

ANTIGENS, CD3; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; HLA-A2 ANTIGEN; HLA-B7 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RETROVIRIDAE; T-LYMPHOCYTES;

EID: 33645517072     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4190     Document Type: Article

References (45)

1. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4.
2. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999;163:507-13.
3. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 2000;74:8207-12.
4. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001;2:962-70.
5. Heemskerk MH, de Paus RA, Lurvink EG, et al. Dual HLA class 1 and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex. Proc Natl Acad Sci U S A 2001;98:6806-11.
6. Heemskerk MH, Hoogeboom M, Hagedoorn R, Kester MG, Willemze R, Falkenburg JH. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med 2004;199:885-94.
7. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002;2:512-9.
8. Kessels HW, Wolkers MC, van den Boom MD, van der Valk MA, Schumacher TN. Immunotherapy through TCR gene transfer. Nat Immunol 2001;2:957-61.
9. Morris EC, Tsallios A, Bendle GM, Xue SA, Stauss HJ. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection. Proc Natl Acad Sci U S A 2005;102:7934-9.
10. van der Veken LT, Hoogeboom M, de Paus RA, Willemze R, Falkenburg JH, Heemskerk MH. HLA class II restricted T-cell receptor gene transfer generates CD4(+) T cells with helper activity as well as cytotoxic capacity. Gene Ther 2005;12:1686-95.
11. Saito T, Hochstenbach F, Marusic-Galesic S, Kruisbeek AM, Brenner M, Germain RN. Surface expression of only γδ and/or αβ T cell receptor heterodimers by cells with four (α, β, γ, δ) functional receptor chains. J Exp Med 1988;168:1003-20.
12. Koning F, Maloy WL, Cohen D, Coligan JE. Independent association of T cell receptor β and γ chains with CD3 in the same cell. J Exp Med 1987;166:595-600.
13. 2-microglobulin- deficient mice. Proc Natl Acad Sci U S A 1992;89:653-7.
14. Bigby M, Markowitz JS, Bleicher PA, et al. Most γδ T cells develop normally in the absence of MHC class II molecules. J Immunol 1993;151:4465-75.
15. Groh V, Porcelli S, Fabbi M, et al. Human lymphocytes bearing T cell receptor γ/δ are phenotypically diverse and evenly distributed throughout the lymphoid system. J Exp Med 1989;169:1277-94.
16. Janeway CA, Jr. The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annu Rev Immunol 1992;10:645-74.
17. Ferrarini M, Ferrero E, Dagna L, Poggi A, Zocchi MR. Human γδ T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002;23:14-8.
18. Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-8.
19. Wilhelm M, Kunzmann V, Eckstein S, et al. γδ T cells for immune therapy of patients with Iymphoid malignancies. Blood 2003;102:200-6.
20. Lamb LS, Jr., Musk P, Ye Z, et al. Human γδ(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant 2001;27:601-6.
21. Dolstra H, Fredrix H, van der Meer A, de Witte T, Figdor C, van de Wiel-van Kemenade E. TCR γδ cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplant 2001;27:1087-93.
22. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A 2003;100:2742-7.
23. + cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 1995;86:2821-8.
24. Vogt MH, van den Muijsenberg JW, Goulmy E, et al. The DBY gene codes for an HLA-DQ5-restricted human male-specific minor histocompatibility antigen involved in graft-versus-host disease. Blood 2002;99:3027-32.
25. Heemskerk MH, Hoogeboom M, de Paus RA, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved α joining region. Blood 2003;102:3530-40.
26. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995;42:455-500.
27. Heemskerk MH, Blom B, Nolan G, et al. Inhibition of T cell and promotion of natural killer cell development by the dominant negative helix loop helix factor Id3. J Exp Med 1997;186:1597-602.
28. Ruggieri L, Aiuti A, Salomoni M, Zappone E, Ferrari G, Bordignon C. Cell-surface marking of CD(34+)-restricted phenotypes of human hematopoietic progenitor cells by retrovirus-mediated gene transfer. Hum Gene Ther 1997;8:1611-23.
29. Kinsella TM, Nolan GP. Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996;7:1405-13.
30. Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, Williams DA. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 1996;2:876-82.
31. Burrows SR, Kienzle N, Winterhalter A, Bharadwaj M, Altman JD, Brooks A. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J Immunol 2000;165:6229-34.
32. Winter H, Hu HM, Urba WJ, Fox BA. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J Immunol 1999;163:4462-72.
33. Seki N, Brooks AD, Carter CR, et al. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J Immunol 2002;168:3484-92.
34. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 2005;17:180-6.
35. Nishimura T, Iwakabe K, Sekimoto M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999;190:617-27.
36. Kessels HW, Wolkers MC, Schumacher TN. Adoptive transfer of T-cell immunity. Trends Immunol 2002;23:264-9.
37. Konig R, Shen X, Germain RN. Involvement of both major histocompatibility complex class II α and β chains in CD4 function indicates a role for ordered oligomerization in T cell activation. J Exp Med 1995;182:779-87.
38. Wang JH, Meijers R, Xiong Y, et al. Crystal structure of the human CD4 N-terminal two-domain fragment complexed to a class II MHC molecule. Proc Natl Acad Sci U S A 2001;98:10799-804.
39. Doyle C, Strominger JL. Interaction between CD4 and class II MHC molecules mediates cell adhesion. Nature 1987;330:256-9.
40. Salter RD, Benjamin RJ, Wesley PK, et al. A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2. Nature 1990;345:41-6.
41. Fragoso R, Ren D, Zhang X, Su MW, Burakoff SJ, Jin YJ. Lipid raft distribution of CD4 depends on its palmitoylation and association with Lck, and evidence for CD4-induced lipid raft aggregation as an additional mechanism to enhance CD3 signaling. J Immunol 2003;170:913-21.
42. Balamuth F, Brogdon JL, Bottomly K. CD4 raft association and signaling regulate molecular clustering at the immunological synapse site. J Immunol 2004;172:5887-92.
43. Arcaro A, Gregoire C, Boucheron N, et al. Essential role of CD8 palmitoylation in CD8 coreceptor function. J Immunol 2000;165:2068-76.
44. + tumor infiltrating lymphocyte. Cancer Res 1999;59:6230-8.
45. + T cells with genuine class I restriction. Eur J Immunol 1992;22:875-8.